Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. (Q45983482)

18 December 2017

title

Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. (English)

1 reference

18 December 2017

author name string

Maria Angela Samis Zella

1

1 reference

18 December 2017

Marta Wallocha

2

1 reference

18 December 2017

Philipp J Slotty

3

1 reference

18 December 2017

Gueler Isik

4

1 reference

18 December 2017

Daniel Hänggi

5

1 reference

18 December 2017

Juliane Schroeteler

6

1 reference

18 December 2017

Christian Ewelt

7

1 reference

18 December 2017

Hans-Jakob Steiger

8

1 reference

18 December 2017

Michael Sabel

9

1 reference

18 December 2017

publication date

28 November 2013

1 reference

18 December 2017

published in

Acta Neurochirurgica

1 reference

18 December 2017

volume

156

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

313-323

1 reference

18 December 2017

Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Incorporating BCNU wafers into malignant glioma treatment: European case studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Efficacy of prophylactic antibiotics for craniotomy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Tumor bed cyst formation after BCNU wafer implantation: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Pharmacokinetics of the carmustine implant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Fatal outcome related to carmustine implants in glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Risk management in the treatment of malignant gliomas with BCNU wafer implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Glioma invasion in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Brain biocompatibility of a biodegradable, controlled-release polymer in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Survival comparison between glioblastoma multiforme and other incurable cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Cerebral edema associated with Gliadel wafers: two case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00701-013-1931-6

10.1007/S00701-013-1931-6

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

Dimensions Publication ID

1009699560

0 references

1 reference

18 December 2017